Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies

Journal of Acquired Immune Deficiency Syndromes

Volumn 7, Issue 9, 1994, Pages 940-951

  Hinkula, Jorma ^a   Bratt, Göran ^b   Gilljam, Gustav ^a   Nordlund, Siv ^a   Broliden, Per Anders ^a   Holmberg, Viveca ^b   Olausson Hansson, Eva ^a   Albert, Jan ^a   Sandström, Eric ^b   Wahren, Britta ^a  

^a National Bacteriological Laboratory   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

HIV 1; Monoclonal antibodies; Passive immunotherapy

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY F58 H3; MONOCLONAL ANTIBODY P4 D10; NEUTRALIZING ANTIBODY; PHYTOHEMAGGLUTININ; TETANUS TOXOID; TUBERCULIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS RNA;

ADULT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG HALF LIFE; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MALE; NAUSEA; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; URTICARIA; VOMITING;

ADULT; AMINO ACID SEQUENCE; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-ANTIBODY COMPLEX; CD4-CD8 RATIO; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; RNA, VIRAL; T-LYMPHOCYTES;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0028170085     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, Haynes BF. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-6.
2. Goudsmit J, Debouck C, Meloen RH, Smit R, Bakker M, Asher DM, Wolff AV, Gibbs CJ, Gajdusek DC. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci USA 1988:85:4478-82.
3. Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, Hoshino H, Javaherian K, Takatsuki K, Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 1988:62:2107-14.
4. Broliden P-A. Mäkitalo B. Åkerblom L, Rosen J, Broliden K, Utter G, Jondal M, Norrby E, Wahren B. Identification of aminoacids in the V3 region of gp 120 critical for virus neutralization by human HIV-1-specific antibodies. Immunology 1991;73:371-6.
5. Åkerblom L, Hinkula J, Broliden P-A. Mäkitalo B, Friberger T, Rosen J. Villacrez-Eriksson. Morein B, Wahren B. Neutralizing cross-reactive and non-neutralizing antibodies to H1V-1 gp 120. AIDS 1990;4:953-60.
6. Ho DD. McKeating JA, Li XL, Moudgil T, Daar ES. Sun N-C, Robinson JE. Conformational epitope on gp 120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65:489-93.
7. Tilley S, Honnen W, Racho M, Hilgartner M, Pinter A. A human monoclonal antibody against the CD4 binding site of HIV-1 gp 120 exhibits potent, broadly neutralizing activity. Res Virol 1991;142:247-59.
8. Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, Sodroski J. Characterization of a discontinuous HIV-1 gp 120 epitope recognized by a broadly neutralizing human monoclonal antibody. J Virol 1991;65:6188-93.
9. Ho DD, Kaplan JC, Rackauskas JE, Gurney ME. Second conserved domain of gp 120 is important for HIV infectivity and antibody neutralization. Science 1988;239:1021-3.
10. Broliden P-A, von Gegerfelt A, Clapham P, Rosen J, Fenyö E-M, Wahren B, Broliden K. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1991;89:461-5.
11. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-7.
12. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, Murthy KK. Prevention of HIV-1 infection in chimpanzees by gp 120 V3 domain specific monoclonal antibody. Nature 1992:355:728-30.
13. Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G, Norrby E. Prevention of HIV-2 and SIVsm in infection by passive immunization in cynomolgus monkeys. Nature 1991;352:436-8.
14. Karpas A, Hill F, Youle M, Cullen V, Gray J, Byron N, Hayhoe F, Tenant-Flowers M, Howard L, Gilgen D, Oates JK, Hawkins D, Gazzard B. Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci USA 1988;1099:9234-7.
15. Karpas A, Hewlett IK, Hill F, Gray J, Byron N, Gilgen D, Bally V, Oates JK, Gazzard B, Epstein JE. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization on patients with AIDS and AIDS-related complex. Proc Natl Acad Sci USA 1990;87:7613-7.
16. Jackson GG, Rubenis M, Knigge M, Perkins JT, Paul DA, Despotes JC, Spencer P. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet 1988:2:647-52.
17. Villecoq D, Mattlinger B, Barré-Sinoussi F, Courouce AM, Rouzioux C, Doniel C, Bary M, Viard JP, Bach JF, Rouger P, Lefrere JJ. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis 1992:165:364-8.
18. Oster K, Wiik A, Black F, Skinhøj P, Kellermann G, Ugen KE, Williams WV, Weiner DB. PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a phase I trial of hyperimmune porcine immunoglobulin to HIV-1. AIDS 1992:6:1457-64.
19. Jacobson JM, Colman N, Ostrow NA, Simson RW, To-mesch D, Marlin L, Rao M, Mills JL, Clemens J, Prince AM. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis 1993; 168:298-305.
20. Broliden P-A, Ljunggren K, Hinkula J, Norrby E, Åkerblom L, Wahren B. A monoclonal antibody to HIV-1 mediating cellular cytotoxicity (ADCC) and neutralization. J Virol 1990;64:936-40.
21. Liou R-S, Rosen E, Fung MS, Sun WNC, Sun C, Gordon W, Chang NT, Chang TW. A chimeric mouse-human antibody that retains specificity for HIV gp 120 and mediates the lysis of HIV-infected cells. J Immunol 1989;143:3967-75.
22. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. An IgG human monoclonal antibody that reacts with HIV-1/gp 120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991;146:4325-32.
23. Sun N-C, Ho DD, Sun CRY, Liou RS, Gordon W, Fung MSC. Li X-L, Ting RC, Lee T-H, Chang NT, Chang TW. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp 120. J Virol 1989;63:3579-85.
24. Javaherian K, Langlois A, Larosa G, Profy A, Bolognesi D, Herliky W, Putney SD, Matthews T. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990;250:1590-3.
25. Ohno T, Terada M, Yoneda Y, et al. Abroadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp 120. Proc Natl Acad Sci USA 1991;88:10726-9.
26. Wahren B, Bratt G, Hinkula J, Gilljam G, Nordlund S, Broliden P-A, Akerblom L, Morein B, Sandström E. Monoclonal antibodies given as passive treatment to HIV-infected individuals. In: Girard M, Valette L, eds. Clinquième Colloque des Cent Gardes. Paris: 1990;263-7.
27. Wahren B, Sandström E, Bratt G, Albert J, Lenkei R, Hinkula J, Gilljam G. Immunotherapy studies of HIV-infected patients with monoclonal antibodies. In: Girard M, Valette L, eds. Clinquième Coliocque des Cent Gardes. Paris: Pasteur Merieux, 1991;305-12.
28. Mellstedt H, Frödin JE, Ragnhammar P, Massucci G, Shetye J, Christensson B, Biberfeld P, Makower P, Ceder-mark B, Harmenberg U, Wahren B, Rieger Å, Magnusson I, Nathansson J, Erwald R. The clinical use of monoclonal antibodies, Mab 17-1A, in the treatment of patients with metastatic colorectal carcinoma. Med Oncol Tumor Phar-macother 1989;6:99-107.
29. Marks JD, Wahren B, Gilljam G, Hinkula J, Winter G. Cloning of an HIV-1 neutralizing V3 specific monoclonal antibody and expression as a mouse-human chimaeric antigen binding fragment and antibody. VIIth International Conference on AIDS, Florence, Italy, 1991, 1162.
30. Hinkula J, Gilljam G, Wahren B. Production of a murine monoclonal antibody with anti-HIV-1 neutralizing properties. J Clin Lab Anal 1991;5:399-406.
31. Gilljam G, Hinkula J, Daniels I, Wahren B. Production and purification of murine monoclonal antibodies directed against HIV-1, for use in passive immunotherapy of HIV-1 infected individuals. International Symposium New generation of monoclonal antibodies in diagnosis and therapy. BIO-TECH-92. Genoa, Italy, 1992:78.
32. Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlén M, Fenyö E-M, Norkrans G. Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals. J Clin Microbiol 1992;30:1768-71.
33. Albert J, Fenyö E-M. Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol 1990;28:1560-4.
34. Brinchmann JE, Albert J, Vartdal F. Few infected CD4+ T cells but a high proportion of replication competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection. J Virol 1991;65:2019-23.
35. Mathiesen T, Sönnerborg A, Wahren B. Detection of antibodies against myelin basic protein and increased levels of HIV-IgG antibodies and HIV antigen after solubilization of immune complexes in sera and CSF of HIV infected patients. Viral Immunol 1989;2:1-11.
36. Sundqvist V-A, Albert J, Ohlsson E, Hinkula L, Fenyö E-M, Wahren B. HIV-lp24 antigen variation in tissue culture of isolates with defined growth characteristics. J Virol 1989;29:170-5.
37. Gilljam G. Envelope glycoproteins of HIV-1, HI V-2 and SIV purified using Galanthus Nivalis agglutinin induce strong immune responses. AIDS Res Hum Retrovir 1993;6:431-8.
38. Frödin J-E, Faxas M-E, Hagström B, Lefvert A-K, Masucci G, Nilsson B, Steinitz M, Unger P, Mellstedt H. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (abl). Relation to the clinical outcome-An important an-titumoral effector function? Hybridoma 1991;10:421-31.
39. Levi M, Sällberg M, Ruden U, Herlyn D, Maruyama H, Wigzell H, Marks J, Wahren B. A complementary-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 1993;(in press).
40. Ljunggren K, Fenyö E-M, Biberfeld G, Jondal M. Detection of antibodies which mediate human immunodeficiency virus-specific cellular cytotoxicity (ADCC) in vitro. J Immunol Methods 1987:104:7-14.
41. Grayeb J, Kato L, McKinney S, Huang JJ, Panda PK, Ho DD, Sarangadharan MG, Chang TW, Chang NT. Human T-cell lymphotropic virus III (HTLV-11I) core antigens: synthesis in E. coli and immunoreactivity with human sera. DNA 1986;5:93-9.
42. Putney SD, Matthews TJ, Robey WG, Lynn DL, Robert-Guroff M, Mueller WT, Langlois AJ, Grayeb SR, Petteway SR, Weinhold KJ, Fishinger PJ, Wong-Staal F, Gallo RC, Bolognesi DP. HTLVIII/LAV-neutralizing antibodies to an E. coli produced fragment of the virus envelope. Science 1986;234:1392-5.
43. Ljungman P, Lönnqvist B, Garton G, Ringden O, Wahren B. Cytomegalovirus-specific lymphocyte proliferation and in vitro cytomegalovirus IgG synthesis for diagnosis of cyto-megalovirus infection after bone marrow transplantation. Blood 1986;88:108-12.
44. Bratt G, Sandström E, Larsson G, Holmberg V, Hinkula J, Gilljam G, Wahren B. A phase I study of infusion of monoclonal antibodies (Mabs) against the V3-region in patients with severe HIV-infection. VIIth International Conference on AIDS, Florence, Italy, 1991, 2147.
45. Peakman M, Senaldi G, Foote N, McManus TJ, Vergani D. Naturally occurring soluble CD4 in patients with human immunodeficiency virus infection. J Infect Dis 1991;165:799-804.
46. Matsuda S, Gidlund M, Chiodi F, Cafaro A, Nygren A, Morein B, Nilsson K, Fenyö E-M, Wigzell H. Enhancement of human immunodeficiency virus (HIV) replication in human monocytes by low titres of anti-HIV antibodies in vitro. Scand J Immunol 1989;30:425-34.
47. Hanson CV, Wrin T, Sawyer L, Crawford L. HIV enhancing antibodies. Presented at the 22nd Keystone symposia, Albuquerque, NM. J Cell Biochem 1993;A429:65.
48. Safrit JT, Fung MSC, Andrews CA, Braun DG, Sun WNC, Chang TW, Koup RA. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp 120. AIDS 1993;7:15-21.
49. Oyaizu N, Chirmule N, Kalyanaraman VS, Hall WW, Good R, Pahwa S. Human immunodeficiency virus type 1 envelope protein gp 120 produces immune defects in CD4 + T-lymphocytes by inhibiting interleukin 2 mRNA. Proc Natl Acad Sci USA 1990;87:2379-83.
50. Redfield R, Birx DC, Ketter W, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A, Wierzba T, Shafferman A, Volvovitz F, Oster C, Burke D. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp 160 in patients with early human immunodeficiency. N Engl J Med 1991;324:1677-84.
51. Losman MJ, DeJager RL, Monestier M, Sharkey RM, Goldenberg DM. Human immune response to anti-car-cinoembryonic antigen murine monoclonal antibodies. Cancer Res 1990;50:1055-8.
52. Thali M, Furman C, Wahren B, Posner M, Ho DD, Robinson J, Sodroski J. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp 120 envelope glycoprotein. J AIDS 1992;5:591-9.
53. Moore JP, Ho DD. Antibodies to discontinuous or confor-mational sensitive epitopes on the gp 120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 1993;67:863-75.